ClinicalTrials.gg
RecruitingNCT05086614Updated Oct 21, 2021

Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

A Phase 3 interventional study of Thymosin Alpha1 in Stage II Colorectal Cancer and Stage III Colorectal Cancer, sponsored by Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-10-21.

Sponsored by Fudan University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Apr 2021, registered Sep 2021).
  • Started Apr 2021; still recruiting 5 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,500
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 127 studies in Colorectal Neoplasms by Fudan University — 68 open to participants now, 72 under way, 8 of them phase 3. Colorectal Neoplasms · Fudan University.

Planned enrollment
Largest of 97
2,500 · median 100
Started
2021
with 13 others
Phase 3
17 of 127
8 open now
Primary completion
2027-03
later than 46 of 71 live
Registered
54th of 127
by date

Among the 127 studies in Colorectal Neoplasms by Fudan University, this one has the largest planned enrollment of the 97 interventional ones that give a count, is one of 14 that started in 2021, is one of 17 in phase 3, reaches primary completion later than 46 of the 71 other live ones, and was the 54th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

68 of the 127 studies in Colorectal Neoplasms by Fudan University are open now, in 1 country. Recruiting first, the newest first:

63 more — sign in →

By country, each count listing its studies:

All 68 open studies →

Where they have run

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Colorectal Neoplasms by Fudan University, or all of them as a file.
02

Study summary

For high-risk stage II and stage III colorectal cancer, even after radical resection and postoperative adjuvant chemo/radiotherapy, 30-40% of patients will still have recurrence and metastasis. Thymosin-alpha 1 is believed to improve immunity and may help promote tumor immunity to reduce the incidence of recurrence and metastasis. This study hopes to verify the effecacy and safety of thymosin-alpha 1 for adjuvant treatment of high-risk stage II and stage III colorectal cancer after radical resection.

Read the detailed description

Patients with pathological high-risk stage II and stage III colorectal cancer after radical resection were randomly allocated to receive thymosin-alpha 1 twice a week for 6 months (experimental group) or not (control group) in a 1:1 ratio. At the same time, all patients will receive chemo/radiotherapy according to the Chinese Standards for Diagnosis and Treatment of Colorectal Cancer. The primary endpoint is 3-year DFS rate.

03

Conditions studied

  • Stage II Colorectal Cancer
  • Stage III Colorectal Cancer

Keywords

  • colorectal cancer
  • adjuvant treatment
  • thymosin-alpha 1
  • disease-free survival
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Colorectal cancer receiving radical resection
  • diagnosed with high-risk stage II or stage III
  • performance status of 0-2
  • Adequate hepatic, renal, and hematologic function

Exclusion criteria

Exclusion Criteria:

  • Had previously taken any immune-promoting drugs
  • Pregnancy or lactation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
2,500 participants (estimated)

Study arms

  • Experimental
    Thymosin

    Patients with pathological high-risk stage II and stage III colorectal cancer after radical resection.

    Drug: Thymosin Alpha1

  • No intervention
    Observe

    Patients with pathological high-risk stage II and stage III colorectal cancer after radical resection.

Interventions

  • DrugThymalfasinStudies of ThymalfasinThymalfasin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Receive thymosin-alpha 1 1.6mg with subcutaneous injection, twice a week, for 6 months after radical resection.

    Also known as: Thymalfasin

06

What researchers measure

Primary outcomes

  1. 3-year disease-free survival rate

    percentage of patients who have no recurrence or metastases or death at 3 years after surgery.

    Time frame: 3 years

Secondary outcomes

  1. 3-year overall survival rate

    percentage of patients who are alive at 3 years after surgery.

    Time frame: 3 years

  2. rate of adverse events related to thymosin-alpha 1

    percentage of patients with adverse events related to thymosin-alpha 1, including fever, allergies, skin rash, liver and kidney damage

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Mar 2027, 71 months after the start.

Of 106 non-industry phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 116. This study's planned 71 months is close to that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2021
First posted
Oct 21, 2021
StartActual
Apr 1, 2021
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Oct 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05086614
Lead sponsor
Fudan University
Responsible party
Sponsor
First posted
Oct 21, 2021
Start date
Apr 1, 2021
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Oct 21, 2021

Study contacts

Jianmin Xu, Dr.
Contact
xujmin@aliyun.com
+86-021-64041990
Qingyang Feng, Dr.
Contact
fqy198921@163.com
+86-021-64041990

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Thymalfasin

Start the discussion